Loading...
OTCMHYPMY
Market cap1.94bUSD
Dec 23, Last price  
2.99USD
1D
9.12%
1Q
-40.32%
Jan 2017
-62.15%
IPO
-79.38%
Name

Hypera SA

Chart & Performance

D1W1MN
OTCM:HYPMY chart
P/E
7.09
P/S
1.48
EPS
2.60
Div Yield, %
40.17%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
16.27%
Revenues
7.91b
+4.88%
346,700,000380,267,0001,061,500,0001,332,994,0002,025,272,0003,159,728,0003,324,630,0003,873,683,0004,258,740,0004,680,348,0002,956,649,0003,288,747,0003,638,458,0003,724,309,0003,294,749,0004,088,871,0005,937,373,0007,546,355,0007,914,658,000
Net income
1.65b
-2.87%
31,000,000-2,932,00042,100,000-207,876,000313,373,000261,901,000-54,651,000203,913,000256,722,000402,695,000559,872,0001,174,574,000964,942,0001,129,601,0001,164,040,0001,295,116,0001,330,208,0001,696,697,0001,647,960,000
CFO
2.40b
+17.52%
85,262,000193,504,00067,236,000580,234,000713,805,000665,785,000664,001,000323,692,000881,756,000932,612,0001,066,494,000823,882,0001,183,054,0001,399,131,0002,038,793,0002,395,993,000
Dividend
Oct 04, 20240.023285 USD/sh
Earnings
Mar 11, 2025

Profile

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
URL
https://www.hypera.com.br/
IPO date
Apr 16, 2008
Employees
9,000
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,914,658
4.88%
7,546,355
27.10%
5,937,373
45.21%
Cost of revenue
4,864,608
4,797,214
3,809,652
Unusual Expense (Income)
NOPBT
3,050,050
2,749,141
2,127,721
NOPBT Margin
38.54%
36.43%
35.84%
Operating Taxes
(141,638)
(95,348)
26,580
Tax Rate
1.25%
NOPAT
3,191,688
2,844,489
2,101,141
Net income
1,647,960
-2.87%
1,696,697
27.55%
1,330,208
2.71%
Dividends
(759,885)
(806,208)
(745,936)
Dividend yield
3.36%
2.90%
4.13%
Proceeds from repurchase of equity
(48,968)
(2,694)
(109,974)
BB yield
0.22%
0.01%
0.61%
Debt
Debt current
2,140,996
2,298,757
602,488
Long-term debt
8,188,010
7,590,623
6,803,883
Deferred revenue
Other long-term liabilities
376,409
405,280
404,082
Net debt
7,627,474
6,895,190
5,008,308
Cash flow
Cash from operating activities
2,395,993
2,038,793
1,399,131
CAPEX
(814,778)
(1,509,456)
(838,882)
Cash from investing activities
(791,188)
(1,742,337)
(4,412,425)
Cash from financing activities
(1,886,385)
278,955
557,058
FCF
2,115,441
1,414,412
540,173
Balance
Cash
2,580,893
2,862,473
2,287,062
Long term investments
120,639
131,717
111,001
Excess cash
2,305,799
2,616,872
2,101,194
Stockholders' equity
11,538,150
10,742,575
9,914,821
Invested Capital
19,699,712
18,212,324
15,542,730
ROIC
16.84%
16.85%
16.11%
ROCE
13.86%
13.20%
12.06%
EV
Common stock shares outstanding
637,793
639,103
639,532
Price
35.44
-18.40%
43.43
53.63%
28.27
-17.46%
Market cap
22,603,384
-18.56%
27,756,243
53.52%
18,079,570
-17.31%
EV
30,244,607
34,661,114
23,094,758
EBITDA
3,288,362
2,918,242
2,261,407
EV/EBITDA
9.20
11.88
10.21
Interest
1,349,523
986,082
383,218
Interest/NOPBT
44.25%
35.87%
18.01%